Clinical trial
A Phase 1/2a Study of the 2S,4R Enantiomer of Ketoconazole in Subjects With Type…
NCT00302224 · DiObex, Industry · Completed
Key facts
| NCT number | NCT00302224 |
|---|---|
| Title | A Phase 1/2a Study of the 2S,4R Enantiomer of Ketoconazole in Subjects With Type 2 Diabetes Mellitus |
| Official title | A Phase 1/2a, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Study of Safety, Tolerability, Pharmacokinetics and Activity of 14 Days of Oral Dosing With the 2S,4R Enantiomer of Ketoconazole (DIO-902) in Subjects With Type 2 Diabetes Mellitus |
| Lead sponsor | DiObex, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes |
| Intervention type | Drug |
| Interventions | 2S, 4R Ketoconazole (DIO-902) |
| Enrollment | 50 |
| Start date | Feb 1, 2005 |
| Completion | Aug 1, 2006 |
| First posted | Mar 14, 2006 |
| Last update posted | Feb 22, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: